An interventional study of Metoprolol (MET) and Plcacebo in ST Segment Elevation Myocardial Infarction (STEMI) and Cardiogenic Shock Post Myocardial Infarction, sponsored by Tel-Aviv Sourasky Medical Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in ST Elevation Myocardial Infarction with a site in Israel — 1 open to participants now, 2 under way, none of them phase 3. ST Elevation Myocardial Infarction · Israel.
Among the 20 studies in ST Elevation Myocardial Infarction with a site in Israel, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 20th registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 200 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →1 of the 20 studies in ST Elevation Myocardial Infarction with a site in Israel is open now.
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 193 across 530 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 106 across the 15 interventional studies, 100 across the 5 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Tel-Aviv Sourasky Medical Center is the lead sponsor of 555 studies on the registry; 52 are open to participants now.
Tel-Aviv Sourasky Medical Center has 2 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies in ST Elevation Myocardial Infarction with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06967194Tel-Aviv Sourasky Medical CenterEarly Beta Blocker Administration in STEMI Patients With SCAI B Status | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in ST Elevation Myocardial Infarction with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.
When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.
During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.
The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.
A prospective, randomized, double-blind cohort study will be conducted on patients with STEMI who are hospitalized in the cardiac intensive care unit and classified as SCAI B at the time of admission by the attending physician. Patients will be identified upon admission to the unit and randomized into two arms - a control group and an intervention group. Randomization will be performed using sealed envelopes. A block randomization model will be used based on LVEF estimation of >40% or ≤40%.
In the intervention group, patients will receive standard beta-blocker treatment, specifically low-dose metoprolol at 25 mg twice daily. In the control group, patients will receive a placebo. All other standard treatments will be identical between the two study groups, in accordance with the unit's treatment protocol and the clinical status of the patients.
As an integral part of this treatment, patients will be continuously monitored for parameters including blood pressure, heart rhythm, and blood lactate levels.
The treatment duration under this protocol will be 72 hours or until the occurrence of the primary outcome, whichever comes first. The primary outcome is defined as progression of the patient's condition to SCAI C, according to accepted criteria, including an increase in lactate levels, a decrease in urine output, or a change in mental status. Per guidelines, every 24 hours, investigators will re-evaluate each patient. If they meet current criteria for beta-blocker administration (SCAI A status and no contraindications), the study drug will be terminated and active metoprolol will be prescribed.
To ensure patient safety, the treating staff will have the option to request unblinding of the patient's allocation at any time. Additionally, after the enrollment of 100 patients (or after one year, whichever comes first), an interim analysis of the data will be conducted to ensure the study remains within established safety parameters.
An echocardiogram and follow-up visit will be performed at 30 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with Metoprolol 25mg
Drug: Metoprolol (MET)
Patients treated with matching placebo
Drug: Plcacebo
Administration of metoprolol 25 mg twice daily
Also known as: metoprolol 25mg
Administration of matching placebo
Also known as: placebo
Number of patients progressed from SCAI B to SCAI C
number of patients who progressed from SCAI B to SCAI C as measured by - Serum lactate levels \> mmol/L urinary output \> 0.5 ml/kg/hour slow capillary filling Change in mental status
Time frame: 3 days from enrollment
Rate of in-hospital mortality
The mortality rate of patients during index admission
Time frame: during index admission - expected up to 7 days
Need for Mechanical ventilation
The rate of patients that will require mechanical ventilation
Time frame: During index admission - expected up to 7 days
Minor adverse events
minor events including tachyarrhythmia, bradyarrhythmia, AV blocks
Time frame: 3 days from enrollment
Hospitalizion duration
Time of index hospitalization
Time frame: During index admission - expected up to 7 days
Ejection fraction at 30 days
Ejection fraction as measured by echocardiography at 30 days
Time frame: 30 days
Plan to share: No — Privacy of participants
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 24 months is below that.
Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metoprolol
ST Elevation Myocardial Infarction →
Tel-Aviv Sourasky Medical Center →